Literature DB >> 22677225

Improved sensitivity of influenza A antigen detection using a combined NP, M, and NS1 sandwich ELISA.

Patumporn Jian-umpunkul1, Charin Thepthai, Nisachon Apiwat, Warangkana Chantima, Kanokwan Poomputsa, Natpapas Wiriyachaiporn, Tararaj Dharakul.   

Abstract

A new modified triple-antigen detection test was developed for the direct detection of the influenza A virus. The nucleoprotein (NP), matrix (M), and non-structural (NS1) proteins were used as target antigens because they are abundant in infected cells. Monoclonal antibodies specific to the NP, M, and NS1 proteins were generated. The antibody pairs were selected and evaluated for their reactivity individually and in combination in the triple-antigen detection using sandwich ELISA. Triple-antigen detection demonstrated a higher sensitivity than individual antigen detection when tested with both the H1N1 and H3N2 influenza A viruses. This was illustrated by the 4-fold lower limit of detection of the triple-antigen test than the individual antigen detection test. The findings demonstrated that the sensitivity of influenza A antigen detection was improved with the triple-antigen detection system as compared to individual antigen detection. Therefore, this technique could be a useful tool for the direct detection of cell-associated influenza A antigen. Furthermore, it could provide a basis for the development of a rapid triple-antigen test for influenza A diagnosis.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22677225     DOI: 10.1016/j.jviromet.2012.05.021

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  1 in total

1.  Identification of a nonstructural DNA-binding protein (DBP) as an antigen with diagnostic potential for human adenovirus.

Authors:  Li Guo; Chengjun Wu; Hongli Zhou; Chao Wu; Gláucia Paranhos-Baccalà; Guy Vernet; Qi Jin; Jianwei Wang; Tao Hung
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.